Drugs / DAVUTAMIG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04077099 | Jan 2020 → Apr 2032 expected | non-small cell lung carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-09-10 | Regeneron Pharmaceuticals | Results Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors regeneron.com ↗
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive early data for two novel and investigational bispecific antibodies – ubamatamab (REGN4018; MUC16xCD3) in recurrent ovarian cancer and REGN5093 (METxMET) in MET-altered advanced non-small cell lung cancer (NSCLC). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-09-10 | Regeneron Pharmaceuticals | Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors regeneron.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAVUTAMIG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095480 ↗ |
| Known as | REGN5093 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04077099 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5095480 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion.” NCT04077099 ↗ |